应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
XFOR X4制药
已收盘 02-06 16:00:00 EST
3.56
-0.10
-2.73%
盘后
3.56
+0.00
0.00%
19:55 EST
最高
3.82
最低
3.52
成交量
83.19万
今开
3.70
昨收
3.66
日振幅
8.09%
总市值
3.11亿
流通市值
2.48亿
总股本
8,744万
成交额
303.71万
换手率
1.20%
流通股本
6,955万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
X4制药盘中异动 快速下挫5.00%报3.80美元
市场透视 · 02-05 03:11
X4制药盘中异动 快速下挫5.00%报3.80美元
X4制药盘中异动 急速下挫5.33%报4.26美元
市场透视 · 2025-12-30
X4制药盘中异动 急速下挫5.33%报4.26美元
X4制药盘中异动 早盘大幅拉升5.05%报3.33美元
市场透视 · 2025-09-22
X4制药盘中异动 早盘大幅拉升5.05%报3.33美元
X4制药将裁员50% 多名高管将离职
格隆汇 · 2025-09-17
X4制药将裁员50% 多名高管将离职
X4制药:作为裁员计划的一部分,首席运营官Mary Dibiase将离开公司
美股速递 · 2025-09-17
X4制药:作为裁员计划的一部分,首席运营官Mary Dibiase将离开公司
X4 Pharmaceuticals宣布重组业务运营以推动长期价值创造
美股速递 · 2025-09-17
X4 Pharmaceuticals宣布重组业务运营以推动长期价值创造
X4制药盘中异动 大幅跳水5.30%
市场透视 · 2025-09-11
X4制药盘中异动 大幅跳水5.30%
X4制药向SEC提交文件,申请由股东出售最多5990万股普通股
美股速递 · 2025-09-11
X4制药向SEC提交文件,申请由股东出售最多5990万股普通股
X4制药盘中异动 股价大跌5.20%
市场透视 · 2025-08-29
X4制药盘中异动 股价大跌5.20%
X4制药盘中异动 大幅下挫6.04%
市场透视 · 2025-08-11
X4制药盘中异动 大幅下挫6.04%
X4制药盘中异动 早盘急速跳水5.09%
市场透视 · 2025-03-10
X4制药盘中异动 早盘急速跳水5.09%
X4制药盘中异动 急速下挫5.00%报0.342美元
市场透视 · 2025-03-04
X4制药盘中异动 急速下挫5.00%报0.342美元
X4制药盘中异动 早盘快速拉升5.47%
市场透视 · 2025-03-03
X4制药盘中异动 早盘快速拉升5.47%
X4制药盘中异动 快速上涨6.55%
市场透视 · 2025-02-28
X4制药盘中异动 快速上涨6.55%
X4制药盘中异动 大幅跳水5.04%
市场透视 · 2025-02-28
X4制药盘中异动 大幅跳水5.04%
X4制药盘中异动 股价大跌5.25%
市场透视 · 2025-02-27
X4制药盘中异动 股价大跌5.25%
X4制药盘中异动 早盘急速跳水5.24%报0.430美元
市场透视 · 2025-02-26
X4制药盘中异动 早盘急速跳水5.24%报0.430美元
X4制药盘中异动 大幅下跌5.14%
市场透视 · 2025-02-24
X4制药盘中异动 大幅下跌5.14%
X4制药盘中异动 早盘股价大涨6.78%报0.543美元
市场透视 · 2025-02-18
X4制药盘中异动 早盘股价大涨6.78%报0.543美元
X4制药盘中异动 股价大涨5.20%报0.506美元
市场透视 · 2025-02-14
X4制药盘中异动 股价大涨5.20%报0.506美元
加载更多
公司概况
公司名称:
X4制药
所属市场:
NASDAQ
上市日期:
--
主营业务:
X4 Pharmaceuticals, Inc.于2010年8月2日根据特拉华州法律注册成立。该公司是一家晚期临床阶段的生物制药公司,发现和开发用于治疗罕见疾病和治疗选择有限的疾病的新疗法,重点关注免疫系统功能障碍导致的疾病。该公司的主要临床候选药物是mavorixafor,这是一种趋化因子受体CXCR4的小分子选择性拮抗剂,正在开发为一种口服、每日一次的疗法。由于mavorixafor能够增加成熟、功能性白细胞进入血液的动员,该公司认为mavorixafor有可能在多种慢性中性粒细胞减少症中提供治疗益处,包括WHIM(疣、低丙种球蛋白血症、感染和骨髓松弛症)综合征,这是一种罕见的原发性免疫缺陷。
发行价格:
--
{"stockData":{"symbol":"XFOR","market":"US","secType":"STK","nameCN":"X4制药","latestPrice":3.56,"timestamp":1770411600000,"preClose":3.66,"halted":0,"volume":831851,"hourTrading":{"tag":"盘后","latestPrice":3.56,"preClose":3.56,"latestTime":"19:55 EST","volume":1020,"amount":3633.4,"timestamp":1770425751778,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.027322404371584723,"floatShares":69550600,"shares":87436700,"eps":-10.5034,"marketStatus":"已收盘","change":-0.1,"latestTime":"02-06 16:00:00 EST","open":3.7,"high":3.82,"low":3.524,"amount":3037117.115785,"amplitude":0.080874,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-10.5034,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1510808400000,"exchange":"NASDAQ","adjPreClose":3.66,"preHourTrading":{"tag":"盘前","latestPrice":3.71,"preClose":3.66,"latestTime":"08:16 EST","volume":6,"amount":22.259999999999998,"timestamp":1770383802434,"change":0.05,"changeRate":0.013661,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":3.56,"preClose":3.56,"latestTime":"19:55 EST","volume":1020,"amount":3633.4,"timestamp":1770425751778,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.525396,"impliedVol":0.72,"impliedVolPercentile":0.8545},"requestUrl":"/m/hq/s/XFOR","defaultTab":"news","newsList":[{"id":"2609040312","title":"X4制药盘中异动 快速下挫5.00%报3.80美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2609040312","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609040312?lang=zh_cn&edition=full","pubTime":"2026-02-05 03:11","pubTimestamp":1770232279,"startTime":"0","endTime":"0","summary":"北京时间2026年02月05日03时11分,X4制药股票出现波动,股价急速跳水5.00%。截至发稿,该股报3.80美元/股,成交量45.8047万股,换手率0.52%,振幅4.50%。机构评级方面,在所有4家参与评级的机构中,100%的券商给予买入建议,无券商给予持有、卖出建议。X4制药股票所在的生物技术行业中,整体涨幅为0.59%。公司还有两种临床前候选药物X4P-003和X4P-002,它们是具有不同性质的CXCR4拮抗剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260205031120a47ce5c4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260205031120a47ce5c4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","XFOR"],"gpt_icon":0},{"id":"2595756766","title":"X4制药盘中异动 急速下挫5.33%报4.26美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2595756766","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595756766?lang=zh_cn&edition=full","pubTime":"2025-12-30 02:21","pubTimestamp":1767032484,"startTime":"0","endTime":"0","summary":"北京时间2025年12月30日02时21分,X4制药股票出现波动,股价快速跳水5.33%。截至发稿,该股报4.26美元/股,成交量14.1842万股,换手率0.16%,振幅4.11%。机构评级方面,在所有4家参与评级的机构中,100%的券商给予买入建议,无券商给予持有、卖出建议。X4制药股票所在的生物技术行业中,整体跌幅为0.62%。公司还有两种临床前候选药物X4P-003和X4P-002,它们是具有不同性质的CXCR4拮抗剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251230022124a486fc8d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251230022124a486fc8d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["XFOR","BK4139"],"gpt_icon":0},{"id":"2569775920","title":"X4制药盘中异动 早盘大幅拉升5.05%报3.33美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2569775920","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569775920?lang=zh_cn&edition=full","pubTime":"2025-09-22 22:43","pubTimestamp":1758552217,"startTime":"0","endTime":"0","summary":"北京时间2025年09月22日22时43分,X4制药股票出现波动,股价快速拉升5.05%。截至发稿,该股报3.33美元/股,成交量8.6009万股,换手率0.38%,振幅6.62%。机构评级方面,在所有4家参与评级的机构中,100%的券商给予买入建议,无券商给予持有、卖出建议。X4制药股票所在的生物技术行业中,整体涨幅为0.66%。公司还有两种临床前候选药物X4P-003和X4P-002,它们是具有不同性质的CXCR4拮抗剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025092222433797a2a0f9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025092222433797a2a0f9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["XFOR","BK4139"],"gpt_icon":0},{"id":"2568249976","title":"X4制药将裁员50% 多名高管将离职","url":"https://stock-news.laohu8.com/highlight/detail?id=2568249976","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568249976?lang=zh_cn&edition=full","pubTime":"2025-09-17 21:12","pubTimestamp":1758114756,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["XFOR","BK4139"],"gpt_icon":0},{"id":"1188959045","title":"X4制药:作为裁员计划的一部分,首席运营官Mary Dibiase将离开公司","url":"https://stock-news.laohu8.com/highlight/detail?id=1188959045","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188959045?lang=zh_cn&edition=full","pubTime":"2025-09-17 19:09","pubTimestamp":1758107353,"startTime":"0","endTime":"0","summary":"X4制药宣布,作为裁员计划的一部分,公司首席运营官Mary Dibiase将离开公司。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XFOR","BK4139"],"gpt_icon":0},{"id":"1132371771","title":"X4 Pharmaceuticals宣布重组业务运营以推动长期价值创造","url":"https://stock-news.laohu8.com/highlight/detail?id=1132371771","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132371771?lang=zh_cn&edition=full","pubTime":"2025-09-17 19:01","pubTimestamp":1758106901,"startTime":"0","endTime":"0","summary":"X4 Pharmaceuticals宣布重组业务运营以推动长期价值创造","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XFOR"],"gpt_icon":0},{"id":"2566936924","title":"X4制药盘中异动 大幅跳水5.30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2566936924","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566936924?lang=zh_cn&edition=full","pubTime":"2025-09-11 21:34","pubTimestamp":1757597642,"startTime":"0","endTime":"0","summary":"北京时间2025年09月11日21时34分,X4制药股票出现异动,股价急速下挫5.30%。截至发稿,该股报3.21美元/股,成交量3.524万股,换手率0.16%,振幅1.22%。机构评级方面,在所有4家参与评级的机构中,100%的券商给予买入建议,无券商给予持有、卖出建议。X4制药股票所在的生物技术行业中,整体涨幅为0.42%。公司还有两种临床前候选药物X4P-003和X4P-002,它们是具有不同性质的CXCR4拮抗剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250911213402a4c11d32&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250911213402a4c11d32&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","XFOR"],"gpt_icon":0},{"id":"1153246602","title":"X4制药向SEC提交文件,申请由股东出售最多5990万股普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1153246602","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153246602?lang=zh_cn&edition=full","pubTime":"2025-09-11 04:19","pubTimestamp":1757535559,"startTime":"0","endTime":"0","summary":"X4制药(X4 Pharmaceuticals Inc)向SEC提交文件,申请由出售股东发售最多5990万股普通股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XFOR"],"gpt_icon":0},{"id":"2563095055","title":"X4制药盘中异动 股价大跌5.20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2563095055","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2563095055?lang=zh_cn&edition=full","pubTime":"2025-08-29 00:03","pubTimestamp":1756397006,"startTime":"0","endTime":"0","summary":"北京时间2025年08月29日00时03分,X4制药股票出现波动,股价快速下挫5.20%。截至发稿,该股报4.01美元/股,成交量32.4352万股,换手率1.44%,振幅8.43%。机构评级方面,在所有3家参与评级的机构中,100%的券商给予买入建议,无券商给予持有、卖出建议。X4制药股票所在的生物技术行业中,整体涨幅为0.04%。公司还有两种临床前候选药物X4P-003和X4P-002,它们是具有不同性质的CXCR4拮抗剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250829000326a4a58f3e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250829000326a4a58f3e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","XFOR","OR","BK4017"],"gpt_icon":0},{"id":"2558651986","title":"X4制药盘中异动 大幅下挫6.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2558651986","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558651986?lang=zh_cn&edition=full","pubTime":"2025-08-11 21:34","pubTimestamp":1754919280,"startTime":"0","endTime":"0","summary":"北京时间2025年08月11日21时34分,X4制药股票出现异动,股价急速下挫6.04%。截至发稿,该股报1.40美元/股,成交量15.1112万股,换手率2.10%,振幅3.36%。机构评级方面,在所有3家参与评级的机构中,100%的券商给予买入建议,无券商给予持有、卖出建议。X4制药股票所在的生物技术行业中,整体跌幅为0.19%。公司还有两种临床前候选药物X4P-003和X4P-002,它们是具有不同性质的CXCR4拮抗剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811213441a6dfb97c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811213441a6dfb97c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","XFOR"],"gpt_icon":0},{"id":"2518271968","title":"X4制药盘中异动 早盘急速跳水5.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518271968","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518271968?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:36","pubTimestamp":1741617417,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时36分,X4制药股票出现波动,股价急速下跌5.09%。截至发稿,该股报0.334美元/股,成交量23.015万股,换手率0.13%,振幅5.57%。机构评级方面,在所有5家参与评级的机构中,100%的券商给予买入建议,无券商给予持有、卖出建议。X4制药股票所在的生物技术行业中,整体涨幅为0.02%。它还拥有两个临床前候选药物X4P-003和X4P-002,它们是具有不同性质的CXCR4拮抗剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310223658a26a3dd0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310223658a26a3dd0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","XFOR"],"gpt_icon":0},{"id":"2517360507","title":"X4制药盘中异动 急速下挫5.00%报0.342美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517360507","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517360507?lang=zh_cn&edition=full","pubTime":"2025-03-04 23:53","pubTimestamp":1741103595,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日23时53分,X4制药股票出现异动,股价大幅下跌5.00%。截至发稿,该股报0.342美元/股,成交量58.3037万股,换手率0.34%,振幅6.02%。机构评级方面,在所有5家参与评级的机构中,100%的券商给予买入建议,无券商给予持有、卖出建议。X4制药股票所在的生物技术行业中,整体跌幅为0.21%。它还拥有两个临床前候选药物X4P-003和X4P-002,它们是具有不同性质的CXCR4拮抗剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304235315989bc18b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304235315989bc18b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","XFOR"],"gpt_icon":0},{"id":"2516632934","title":"X4制药盘中异动 早盘快速拉升5.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516632934","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516632934?lang=zh_cn&edition=full","pubTime":"2025-03-03 22:34","pubTimestamp":1741012452,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日22时34分,X4制药股票出现异动,股价大幅上涨5.47%。截至发稿,该股报0.417美元/股,成交量11.791万股,换手率0.07%,振幅4.56%。X4制药股票所在的生物技术行业中,整体涨幅为0.38%。X4制药公司简介:X4 Pharmaceuticals Inc 是一家后期临床生物制药公司,致力于研究和开发治疗罕见疾病和治疗选择有限的疾病的新型疗法,重点关注由免疫系统功能障碍引起的疾病。它还拥有两个临床前候选药物X4P-003和X4P-002,它们是具有不同性质的CXCR4拮抗剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303223412abe63432&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303223412abe63432&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["XFOR","BK4139"],"gpt_icon":0},{"id":"2514337651","title":"X4制药盘中异动 快速上涨6.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514337651","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514337651?lang=zh_cn&edition=full","pubTime":"2025-02-28 23:18","pubTimestamp":1740755898,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日23时18分,X4制药股票出现异动,股价大幅上涨6.55%。截至发稿,该股报0.394美元/股,成交量57.3175万股,换手率0.34%,振幅7.93%。X4制药股票所在的生物技术行业中,整体涨幅为0.26%。X4制药公司简介:X4 Pharmaceuticals Inc 是一家后期临床生物制药公司,致力于研究和开发治疗罕见疾病和治疗选择有限的疾病的新型疗法,重点关注由免疫系统功能障碍引起的疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228231819abe0f638&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228231819abe0f638&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","XFOR"],"gpt_icon":0},{"id":"2514363143","title":"X4制药盘中异动 大幅跳水5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514363143","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514363143?lang=zh_cn&edition=full","pubTime":"2025-02-28 02:27","pubTimestamp":1740680861,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日02时27分,X4制药股票出现异动,股价快速下挫5.04%。截至发稿,该股报0.386美元/股,成交量112.264万股,换手率0.66%,振幅7.84%。机构评级方面,在所有5家参与评级的机构中,100%的券商给予买入建议,无券商给予持有、卖出建议。X4制药股票所在的生物技术行业中,整体涨幅为0.22%。它还拥有两个临床前候选药物X4P-003和X4P-002,它们是具有不同性质的CXCR4拮抗剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228022741a256b15a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228022741a256b15a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["XFOR","BK4139"],"gpt_icon":0},{"id":"2514286864","title":"X4制药盘中异动 股价大跌5.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514286864","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514286864?lang=zh_cn&edition=full","pubTime":"2025-02-27 04:00","pubTimestamp":1740600000,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日04时00分,X4制药股票出现异动,股价大幅下挫5.25%。截至发稿,该股报0.413美元/股,成交量97.6292万股,换手率0.57%,振幅7.93%。X4制药股票所在的生物技术行业中,整体跌幅为0.63%。X4制药公司简介:X4 Pharmaceuticals Inc 是一家后期临床生物制药公司,致力于研究和开发治疗罕见疾病和治疗选择有限的疾病的新型疗法,重点关注由免疫系统功能障碍引起的疾病。它还拥有两个临床前候选药物X4P-003和X4P-002,它们是具有不同性质的CXCR4拮抗剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227040000abde3455&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227040000abde3455&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["XFOR","BK4139"],"gpt_icon":0},{"id":"2514821011","title":"X4制药盘中异动 早盘急速跳水5.24%报0.430美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514821011","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514821011?lang=zh_cn&edition=full","pubTime":"2025-02-26 00:17","pubTimestamp":1740500257,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日00时17分,X4制药股票出现异动,股价急速跳水5.24%。截至发稿,该股报0.430美元/股,成交量34.3005万股,换手率0.20%,振幅6.13%。机构评级方面,在所有5家参与评级的机构中,100%的券商给予买入建议,无券商给予持有、卖出建议。X4制药股票所在的生物技术行业中,整体涨幅为0.65%。它还拥有两个临床前候选药物X4P-003和X4P-002,它们是具有不同性质的CXCR4拮抗剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226001737a2539f4e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226001737a2539f4e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["XFOR","BK4139"],"gpt_icon":0},{"id":"2513442720","title":"X4制药盘中异动 大幅下跌5.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513442720","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513442720?lang=zh_cn&edition=full","pubTime":"2025-02-24 22:55","pubTimestamp":1740408942,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日22时55分,X4制药股票出现波动,股价快速跳水5.14%。截至发稿,该股报0.443美元/股,成交量22.5575万股,换手率0.13%,振幅9.21%。机构评级方面,在所有5家参与评级的机构中,100%的券商给予买入建议,无券商给予持有、卖出建议。X4制药股票所在的生物技术行业中,整体涨幅为0.12%。它还拥有两个临床前候选药物X4P-003和X4P-002,它们是具有不同性质的CXCR4拮抗剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224225542962e9ee5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224225542962e9ee5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","XFOR"],"gpt_icon":0},{"id":"2512165772","title":"X4制药盘中异动 早盘股价大涨6.78%报0.543美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512165772","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512165772?lang=zh_cn&edition=full","pubTime":"2025-02-18 22:43","pubTimestamp":1739889784,"startTime":"0","endTime":"0","summary":"北京时间2025年02月18日22时43分,X4制药股票出现波动,股价大幅拉升6.78%。截至发稿,该股报0.543美元/股,成交量16.9739万股,换手率0.10%,振幅5.37%。最近的财报数据显示,该股实现营业收入560000.00美元,净利润-36.70百万美元,每股收益-0.18美元,毛利253000.00美元,市盈率-6.79倍。X4制药股票所在的生物技术行业中,整体涨幅为0.60%。它还拥有两个临床前候选药物X4P-003和X4P-002,它们是具有不同性质的CXCR4拮抗剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218224304abd3b1da&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218224304abd3b1da&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["XFOR","BK4139"],"gpt_icon":0},{"id":"2511578121","title":"X4制药盘中异动 股价大涨5.20%报0.506美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2511578121","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511578121?lang=zh_cn&edition=full","pubTime":"2025-02-14 01:16","pubTimestamp":1739467003,"startTime":"0","endTime":"0","summary":"北京时间2025年02月14日01时16分,X4制药股票出现波动,股价急速拉升5.20%。截至发稿,该股报0.506美元/股,成交量44.3566万股,换手率0.26%,振幅4.72%。最近的财报数据显示,该股实现营业收入560000.00美元,净利润-36.70百万美元,每股收益-0.18美元,毛利253000.00美元,市盈率-6.25倍。X4制药股票所在的生物技术行业中,整体涨幅为0.89%。它还拥有两个临床前候选药物X4P-003和X4P-002,它们是具有不同性质的CXCR4拮抗剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021401164498844c68&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021401164498844c68&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","XFOR"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.x4pharma.com","stockEarnings":[{"period":"1week","weight":-0.0081},{"period":"1month","weight":-0.0758},{"period":"3month","weight":-0.0135},{"period":"6month","weight":1.4564},{"period":"1year","weight":-0.8022},{"period":"ytd","weight":-0.085}],"compareEarnings":[{"period":"1week","weight":-0.0237},{"period":"1month","weight":-0.0205},{"period":"3month","weight":0.0099},{"period":"6month","weight":0.0635},{"period":"1year","weight":0.1215},{"period":"ytd","weight":-0.0063}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"X4 Pharmaceuticals, Inc.于2010年8月2日根据特拉华州法律注册成立。该公司是一家晚期临床阶段的生物制药公司,发现和开发用于治疗罕见疾病和治疗选择有限的疾病的新疗法,重点关注免疫系统功能障碍导致的疾病。该公司的主要临床候选药物是mavorixafor,这是一种趋化因子受体CXCR4的小分子选择性拮抗剂,正在开发为一种口服、每日一次的疗法。由于mavorixafor能够增加成熟、功能性白细胞进入血液的动员,该公司认为mavorixafor有可能在多种慢性中性粒细胞减少症中提供治疗益处,包括WHIM(疣、低丙种球蛋白血症、感染和骨髓松弛症)综合征,这是一种罕见的原发性免疫缺陷。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.010739},{"month":2,"riseRate":0.555556,"avgChangeRate":0.014144},{"month":3,"riseRate":0.5,"avgChangeRate":0.070477},{"month":4,"riseRate":0.25,"avgChangeRate":-0.02608},{"month":5,"riseRate":0.25,"avgChangeRate":-0.040791},{"month":6,"riseRate":0.125,"avgChangeRate":-0.268932},{"month":7,"riseRate":0.25,"avgChangeRate":-0.039863},{"month":8,"riseRate":0.375,"avgChangeRate":0.07504},{"month":9,"riseRate":0.25,"avgChangeRate":-0.001382},{"month":10,"riseRate":0.25,"avgChangeRate":-0.084011},{"month":11,"riseRate":0.25,"avgChangeRate":0.161316},{"month":12,"riseRate":0.444444,"avgChangeRate":-0.049964}],"exchange":"NASDAQ","name":"X4制药","nameEN":"X4 Pharmaceuticals Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"X4制药(XFOR)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供X4制药(XFOR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"X4制药,XFOR,X4制药股票,X4制药股票老虎,X4制药股票老虎国际,X4制药行情,X4制药股票行情,X4制药股价,X4制药股市,X4制药股票价格,X4制药股票交易,X4制药股票购买,X4制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"X4制药(XFOR)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供X4制药(XFOR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}